SPECIALTY TOPICS · GUIDE
Serotonergic Medicines and Substance-Specific Evidence
Content last updated . This page has not been medically reviewed.
Back to Psychedelic TherapyUrgent help first
Serotonin syndrome is a potentially life-threatening reaction that most often occurs when two or more medicines or drugs that affect serotonin are taken together. [1] Symptoms occur within minutes to hours and can include agitation, abnormal eye movements, diarrhea, fast heartbeat, high blood pressure, hallucinations, increased body temperature, loss of coordination and overactive reflexes. [1] In the US call 911 for an emergency; US Poison Help is 1-800-222-1222. MedlinePlus advises not to stop a medicine without first talking to a provider. [1] This page is education only and never tells anyone to start, stop or change a medicine.Why one chart does not work
"Serotonergic" covers very different drugs. [3] Antidepressants are another class again. A 2022 review concluded that risks differ: serotonergic drugs without MAOIs are low risk with psychedelics without MAOIs, while some combinations carry significant risk of serotonin toxicity and others are likely benign. [4] NIDA adds that reported cases of psychedelic drug interactions are exceedingly rare and that some researchers suspect interactions with serotonin-raising prescription medicines. [2]That is why this page goes substance by substance. Evidence labels used: promising but limited, mixed, insufficient evidence, evidence of harm. See how we label evidence.
Substance by substance
| Pairing | What was studied | What it showed | Label |
|---|---|---|---|
| Psilocybin and an SSRI (escitalopram) | Randomized crossover study in healthy people, escitalopram for 14 days, then psilocybin (25 mg, a study amount) | No relevant effect on positive mood effects; fewer bad drug effects, less anxiety and fewer adverse cardiovascular effects than with placebo pretreatment [5] | promising but limited |
| Ayahuasca and SSRIs or other serotonergic medicines | Warning paper, case report, modeling | Possible serious serotonin syndrome; see the MAO page [7] | evidence of harm in a case report |
The psilocybin result is the most important for readers who assume a combination is dangerous: in this one small study, the SSRI did not increase risks, but the authors said longer antidepressant pretreatment and studies in patients with psychiatric disorders are needed. [5] The study cannot say what happens with other antidepressants, other doses, long-term use or people with depression.
What systematic reviews say about the whole evidence base
A 2022 systematic review included 40 publications: 26 randomized studies in healthy adults, 3 epidemiologic studies and 11 case reports. [6] Participants in the trials were young healthy adults given a psychiatric medicine once or, rarely, for up to 14 days, so the findings are limited when extrapolating to real-world settings where medicines are taken daily for months or years. [6]For ayahuasca, which contains an MAO inhibitor, see MAO-inhibiting preparations and interactions.
Other medicines and groups
- MAOI antidepressants: the label for one MAOI says it should not be used together with serotonin-acting agents because serious, sometimes fatal reactions have been reported. [9]
- Cough and cold ingredients and pain medicines: MedlinePlus says MAOIs can cause serotonin syndrome with medicines including meperidine, fentanyl and dextromethorphan. [1]
What the evidence cannot say
- Whether results in healthy volunteers apply to people with depression, anxiety or PTSD.
- What happens after months of antidepressant treatment, since the longest exposure in the controlled studies was short.
- Whether any particular product sold outside medicine contains what its label claims. See contamination and adulteration.
For related pages see psychedelic drug interactions and toxicology, interactions by drug class and talking with a health professional.
Frequently asked questions
Is it safe to combine psilocybin with an antidepressant?
This page cannot say that. In one randomized crossover study of healthy adults, escitalopram pretreatment did not reduce positive effects and reduced bad drug effects and adverse effects, but the authors called for more studies in patients. [5]
Why do trials exclude people on antidepressants?
Exclusions or tapers keep studies controlled. They do not show how a combination behaves, and one US trial let participants on psychotropic medicines in after a supervised taper. [8]
What is serotonin syndrome?
A potentially life-threatening reaction in which the body has too much serotonin, most often when two or more serotonin-affecting medicines or drugs are combined. [1]
Should I stop my medicine before taking a psychedelic?
No source here recommends that, and we do not give stopping advice. Talk with the prescriber. [1]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Trial exclusion is not interaction evidence
An exclusion or a taper step in a protocol shows that researchers wanted a controlled setting. It does not measure how a given combination behaves, and it is not advice for anyone outside the study. Only a prescriber who knows the person can decide about medicines.
References
- MedlinePlus Medical Encyclopedia, Serotonin syndrome. Read 2026-10-22.
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
- Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics. Psychopharmacology 2022. Read 2026-10-22.
- Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther 2022. Read 2026-10-22.
- Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs 1998. Read 2026-10-22.
- Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 2023. Read 2026-10-22.
- US Food and Drug Administration drug label data (openFDA), Phenelzine Sulfate Tablets label, label version effective 2017-09-29. Read 2026-10-22.